Advertisement
Canada markets open in 7 hours 39 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7307
    +0.0009 (+0.12%)
     
  • CRUDE OIL

    82.96
    +0.15 (+0.18%)
     
  • Bitcoin CAD

    88,056.87
    -3,268.20 (-3.58%)
     
  • CMC Crypto 200

    1,389.04
    -35.06 (-2.46%)
     
  • GOLD FUTURES

    2,328.60
    -9.80 (-0.42%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    -4.5980 (-49.71%)
     
  • NASDAQ futures

    17,436.75
    -227.75 (-1.29%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,642.45
    -817.63 (-2.13%)
     
  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

A Post-3Q17 Update on Key Valeant Branded Drugs: Xifaxan, Apriso, and Glumetza

In 3Q17, Valeant’s Xifaxan reported revenues of $286 million, which was ~5% higher on a YoY (year-over-year) basis and a 23% rise quarter-over-quarter.